Livzon Pharmaceutical Group Inc. (LVZPF) Stock Analysis

Livzon Pharmaceutical Group Inc. (LVZPF) Healthcare & Pipeline Overview

Livzon Pharmaceutical Group Inc., based in China, develops, manufactures, and markets a diverse range of pharmaceutical products, including APIs, diagnostic reagents, and traditional Chinese medicines, targeting key therapeutic areas such as assisted reproduction, gastrointestinal health, and psychiatric disorders, with a growing international presence.

What Is the Investment Thesis for LVZPF?

Livzon Pharmaceutical Group Inc. presents a notable research candidate due to its diversified product portfolio, strong presence in the Chinese pharmaceutical market, and expanding international reach. The company's focus on key therapeutic areas such as assisted reproduction and gastrointestinal health positions it well to capitalize on growing demand for these treatments. With a profit margin of 18.1% and an ROE of 16.4%, Livzon demonstrates strong profitability and efficient capital utilization. The company's low beta of 0.39 suggests relatively low volatility compared to the overall market. Upcoming catalysts include potential regulatory approvals for new products and expansion into new geographic markets. However, investors should be aware of potential risks such as regulatory changes in China and increased competition from other pharmaceutical companies.

Based on FMP financials and quantitative analysis

LVZPF Key Highlights

Market capitalization of $6.06B reflects Livzon's significant presence in the pharmaceutical industry.

• Profit margin of 18.1% indicates strong profitability and efficient cost management.
• Gross margin of 64.5% demonstrates the company's ability to generate revenue from its products and services.
• Return on Equity (ROE) of 16.4% signifies effective utilization of shareholder equity to generate profits.
• Debt-to-equity ratio of 25.49 indicates a moderate level of financial leverage.

Who Are LVZPF's Competitors?

LVZPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are LVZPF's Key Strengths?

Diversified product portfolio.

• Strong presence in the Chinese market.
• Established manufacturing capabilities.
• Research and development capabilities.

What Are LVZPF's Weaknesses?

Reliance on the Chinese market.

• Exposure to regulatory changes in China.
• Limited brand recognition in international markets.
• Dependence on third-party distributors.

What Could Drive LVZPF Stock Higher?

Potential regulatory approvals for new pharmaceutical products in China.

• Expansion into new international markets, particularly in Southeast Asia.
• Increasing demand for assisted reproductive technology (ART) services in China.
• Growing prevalence of gastrointestinal disorders driving demand for related treatments.

What Are the Key Risks for LVZPF?

Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.

• Changes in Chinese pharmaceutical regulations could impact profitability.
• Increased competition from domestic and international pharmaceutical companies.
• Intellectual property infringement could erode market share.
• Fluctuations in currency exchange rates could affect international sales.
• Dependence on key suppliers for APIs and raw materials.

What Are the Growth Opportunities for LVZPF?

• Expansion in the Assisted Reproduction Market: The global assisted reproductive technology (ART) market is projected to reach $45 billion by 2030, driven by increasing infertility rates and rising awareness of ART procedures. Livzon's existing portfolio of fertility drugs, including leuprorelin acetate microspheres, urofollitropin, and menotropins, positions it well to capture a larger share of this growing market. Strategic partnerships with fertility clinics and increased marketing efforts could further enhance Livzon's market penetration.
• Growth in the Gastrointestinal Drug Market: The global gastrointestinal drugs market is expected to reach $55 billion by 2027, fueled by the rising prevalence of gastrointestinal disorders such as acid reflux, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD). Livzon's Ilaprazole enteric-coated tablets and bismuth potassium citrate products address these conditions, providing a solid foundation for growth in this market. Further research and development of innovative gastrointestinal therapies could create additional growth opportunities.
• Increased Focus on Traditional Chinese Medicine (TCM): The global market for traditional medicine is experiencing a resurgence, driven by increasing consumer interest in natural and holistic healthcare solutions. Livzon's shenqi fuzheng injection and anti-viral granules cater to this demand, offering a unique value proposition in the market. Investing in research to validate the efficacy of TCM products and expanding distribution channels could unlock significant growth potential.
• Expansion into International Markets: While Livzon already exports its products internationally, there is significant potential to further expand its geographic reach. Targeting emerging markets with growing healthcare expenditure and unmet medical needs could drive substantial revenue growth. Establishing strategic partnerships with local distributors and adapting products to meet local regulatory requirements are crucial for successful international expansion.
• Development of Novel Diagnostic Reagents: The global diagnostics market is experiencing rapid growth, driven by technological advancements and increasing demand for early and accurate disease detection. Livzon's existing portfolio of diagnostic reagents, including kits for detecting infectious diseases and autoimmune disorders, provides a strong foundation for growth in this market. Investing in research and development to create novel diagnostic tools and expanding distribution networks could drive significant revenue growth.

What Threats Does LVZPF Face?

• Increased competition from other pharmaceutical companies.
• Stringent regulatory requirements.
• Price pressures from generic drugs.
• Intellectual property infringement.

What Are LVZPF's Competitive Advantages?

• Diversified product portfolio across multiple therapeutic areas.
• Strong presence in the Chinese pharmaceutical market.
• Established manufacturing capabilities for APIs and pharmaceutical products.
• Research and development capabilities for creating new products.
• Established distribution network in China and internationally.

What Does LVZPF Do?

Livzon Pharmaceutical Group Inc., established in 1985 and headquartered in Zhuhai, China, is a comprehensive pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products, active pharmaceutical ingredients (APIs), and intermediates. The company's origins lie in the growing Chinese pharmaceutical market, where it initially focused on developing and manufacturing essential medicines. Over the years, Livzon has expanded its product portfolio to include a wide array of therapeutic areas, including assisted reproduction, gastrointestinal health, psychiatric and neurological conditions, and traditional Chinese medicine. Livzon's key products include leuprorelin acetate microspheres, urofollitropin, and menotropins for injection, which are used in the assisted reproduction field. For gastrointestinal health, it offers Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products. In the psychiatric and neurological field, Livzon provides fluvoxamine maleate and perospirone hydrochloride tablets. The company also produces traditional Chinese medicine products such as shenqi fuzheng injection and anti-viral granules. Furthermore, Livzon manufactures APIs and intermediates, including mevastatin, acarbose, phenylalanine, vancomycin hydrochloride, daptomycin, milbemycin oxime, and ceftriaxone sodium. The company also offers a range of diagnostic reagents, including diagnostic kits for IgM antibody to mycoplasma pneumonia, human immunodeficiency virus antibody, and antinuclear antibody test kits. Livzon's geographic reach extends beyond China, with exports to international markets.

What Products and Services Does LVZPF Offer?

• Researches and develops pharmaceutical products.
• Produces a range of pharmaceutical products, including drugs and APIs.
• Exports pharmaceutical products to international markets.
• Sells pharmaceutical products in the People's Republic of China.
• Manufactures active pharmaceutical ingredients (APIs) and intermediates.
• Offers diagnostic reagents and kits for various diseases.

How Does LVZPF Make Money?

• Develops and manufactures pharmaceutical products, APIs, and diagnostic reagents.
• Sells products through distributors and directly to healthcare providers.
• Generates revenue from both domestic and international sales.
• Invests in research and development to create new products and improve existing ones.

What Industry Does LVZPF Operate In?

Livzon Pharmaceutical Group Inc. operates in the global pharmaceutical industry, which is characterized by intense competition, stringent regulatory requirements, and rapid technological advancements. The Chinese pharmaceutical market, in particular, is experiencing significant growth due to increasing healthcare expenditure and an aging population. Livzon competes with both domestic and international pharmaceutical companies, including generic drug manufacturers and innovative drug developers. The company's focus on specialty and generic drugs, as well as traditional Chinese medicine, allows it to cater to a broad range of patient needs. The global pharmaceuticals market is projected to reach $1.7 trillion by 2028, growing at a CAGR of 5%.

Who Are LVZPF's Key Customers?

• Hospitals and clinics
• Pharmacies and drug stores
• Healthcare providers

Company Profile

Livzon Pharmaceutical Group Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Zhuhai, CN. The company is led by CEO Daping Liu. LVZPF has traded publicly since 2018.

Livzon Pharmaceutical Group Inc. Financial Trajectory

Livzon Pharmaceutical Group Inc. (LVZPF) reported $316.6M in revenue for Q2 FY2026, a decline of 25.4% compared to the prior quarter. The company recorded net income of $52.8M, with diluted EPS of $0.06. Revenue has contracted over three consecutive quarters, which investors in this mid-cap Healthcare stock should monitor closely. Across the four most recent quarters, LVZPF averaged $0.07 in diluted EPS.

How Livzon Pharmaceutical Group Inc. Is Valued

Livzon Pharmaceutical Group Inc. carries a market capitalization of $6.06B, placing it in the mid-cap category.

Return on equity for Livzon Pharmaceutical Group Inc. stands at 14.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.1%, showing how much profit it generates from its asset base. LVZPF trades at a trailing price-to-earnings ratio of 14.08, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 10.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.5%, the inverse of the P/E and a quick read on earnings relative to price.

Livzon Pharmaceutical Group Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.45 places it in the safe zone, indicating low near-term bankruptcy risk.

Livzon Pharmaceutical Group Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 7.3% below estimates on average.

LVZPF Financials

LVZPF Latest News

No recent news available for LVZPF.

LVZPF Analyst Consensus

LVZPF MoonshotScore

LVZPF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources